DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for substance abuse — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSubstance abuse maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for substance abuse is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alcohol dehydrogenase 1C (class I), gamma polypeptide (ADH1C) — ADH1C is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet naddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1U3W · 1.45 Å · ligand NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD). Experimental structure, not a prediction.
What the evidence adds up to
A 1982 study of 742 patients treated in six programmes and evaluated at six-month follow-up found significant and pervasive improvements in alcohol and drug use, employment, criminal behaviour, and psychological function. Patients undergoing long-term treatment showed greater improvement and better six-month outcomes than those undergoing short-term therapy on 12 of 18 criteria. The authors concluded the data provided evidence for the therapeutic benefit of substance abuse treatments, but noted that few studies had adequately assessed effectiveness using an appropriate range of reliable outcome measures.
A 2006 review of large-scale national evaluation studies, including the Drug Abuse Treatment Outcomes Studies, stated that such studies provide a broad view of treatment services in community-based programmes but do not address the implementation or effectiveness of specific clinical treatment approaches. The authors noted these studies are best suited to examining global questions about patient characteristics and outcomes, and can help identify gaps in existing treatment systems.
A 2007 article discussed medication as an increasingly accepted adjunct to drug abuse treatment, partly due to frustration in treating crack cocaine abusers and the integration of drug abuse treatment into mainstream medicine. The article described medications in use for addictive disease and suggested more cost-effective methods of exploring medication efficacy, but did not report any specific trial results or response rates. A 2005 article on substance abuse among nurses provided suggestions for confronting peers, documenting behaviours, and reporting to managers, but contained no outcome data.
A 1994 review of a book on genetics and substance abuse stated that the determinant role of genetics on behavioural and biochemical responses is an increasingly pertinent area of research, but provided no experimental results. What is still missing are adequately powered randomised controlled trials that compare specific medications or treatment durations against placebo, reliable biomarkers to stratify patients by genetic or metabolic profile, and funding for long-term follow-up studies that can distinguish treatment effects from natural recovery.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1982 · 198 citations
Is Treatment for Substance Abuse Effective?
AbstractFew studies have assessed adequately the effectiveness of alcohol and drug abuse treatments using an appropriate range of reliable outcome measures, a representative sample of alcohol and drug abuse treatment modalities, or more than one perspective on treatment effectiveness. This article evaluates substance abuse treatment using a sample of 742 patients treated in six programs and evaluated at six-month follow-up. The following three major questions were addressed: (1) do patients improve following treatment; (2) are improvements confined to alcohol or drug use, or are they more pervasive; and (3) are these improvements a result of treatment? The results indicated significant and pervasive improvements in virtually all areas for both alcoholics and drug addicts. Major changes were seen in alcohol and drug use, employment, criminal behavior, and psychological function. Patients undergoing long-term treatment showed greater improvement and better six-month outcomes than those undergoing short-term therapy on 12 of 18 criteria. The data provide evidence for the therapeutic benefit of substance abuse treatments.
Substance abuse among nurses—Intercession and intervention
AbstractIT IS NOT EASY to report a coworker who may have a substance abuse problem, so many nurses choose to remain silent about this issue. THIS ARTICLE PROVIDES suggestions for staff nurses about how to confront a peer, document inappropriate nursing behaviors related to substance abuse, and report these issues to a manager. The manager's role in counseling and intercession with a substance abusing employee also is detailed. REMEDIATION AND SUPPORT programs are addressed along with return-to-work issues and the need for education about this debilitating disease.
Cambridge University Press eBooks · 2006 · 10 citations
The Drug Abuse Treatment Outcomes Studies: outcomes with adolescent substance abusers
AbstractLarge-scale studies of drug abuse treatment effectiveness provide benchmarks that can be used to gauge drug abuse treatment services at a given point in time, as well as over time. Such large-scale studies have inherent strengths and weaknesses: they provide a broad view of the nature of treatment services offered in community-based programs, yet, because of their breadth, they do not address the implementation or effectiveness of specific clinical treatment approaches. Consequently, national evaluation studies are best suited to examining global questions about the characteristics of individuals who utilize substance abuse treatment across a broad sample of settings and the outcomes associated with their treatment participation. Findings from these studies can help to advance the field by identifying gaps in existing treatment systems and, by informing the development of both clinical and policy approaches, to improve the quality of treatment provided.
Kanrin : Bulletin of the Japan Society of Naval Architects and Ocean Engineers · 2007 · 0 citations
日本への原油の動き( 海を越えて運ぶ「タンカー」)
AbstractMedication has become an increasingly accepted adjunct to other forms of drug abuse treatment. Its acceptance is due in part to clinicians' frustration in treating crack cocaine abusers and to increasing integration of drug abuse treatment into mainstream medicine. A rapidly growing body of literature attests to clinical researchers' interest in pharmacotherapy of substance abuse. Medications can be a useful adjunct to drug abuse treatment in many different ways. The clinical challenge is to decide who should be treated with what medication and at what stage of recovery medications are helpful. This article discusses medications currently in use for treatment of addictive disease, describes some aspects of medication development, and suggests more cost-effective methods of exploring the efficacy of medications for treatment of drug abuse.
AbstractReviews the book, Behavioral and Biochemical Issues in Substance Abuse edited by Frank R. George, Doris Clouet, and Barry Stimmel (1991). The determinant role of genetics on behavioral and biochemical responses in substance abuse is an extremely interesting and increasingly pertinent area of research. This is the main topic and focus of this book. This book provides an excellent overview of the power of genetic experimental designs, the results that can be generated as well as the cautions that must be observed in this approach. The editors have combined an independent collection of works in a cohesive, enlightening, thorough text that is an asset to the substance abuse field.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
